The history of the erectile dysfunction drug presents a intricate picture for investors. While the initial introduction generated massive profits, the lapse of its patent opened the avenue to cheaper competitors, dramatically reducing market share. This presents a unique risk for pharmaceutical companies relying on similar blockbuster medications,

The history of Viagra, and its creator copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in income, its patent expiration created a wave of generic competition , significantly diminishing its dominance. While some pharmaceutical companies may try to capitalize on related treatments , the exis